Teva Specialty & Biosimilar Pipeline
By development stage – as of July 15, 2022
Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strength in generics with our knowledge of innovative drug development. We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments, offer innovative solutions, and find new ways to extend and expand patient care beyond medicine.
Technology Platforms:
Under Regulatory Review
Pre Submission
Phase 3
Phase 2
Phase 1
Pre-clinical
Download a PDF version of Teva Specialty and Biosimilar Pipeline
Download PDFTeva specialty and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
Pipeline is current as of July 15, 2022
-
Back to contents.
In collaboration with Alvotech for the US market.
-
Back to contents.
In collaboration with Regeneron.
-
Back to contents.
This use is investigational.
-
Back to contents.
In collaboration with MODAG.
-
Back to contents.
In collaboration with BioEq in UK (marketed as ONGAVIA®), Europe (under regulatory review) and Canada (expected submission in late 2022).
